Alexion snags option to buy neurodegeneration startup Complement

Alexion has secured the option to acquire Dutch biotech Complement Pharma. The agreement will see Alexion work with Complement to take a C6 complement inhibitor through phase 1b and decide whether to pull the trigger on a takeover along the way.